公开(公告)号：US20190152988A1

公开(公告)日：2019-05-23

申请号：US16171606

申请日：2018-10-26

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D487/04 ,  C07D417/12 ,  C07D409/12 ,  C07D239/49 ,  C07D239/42 ,  C07D403/14 ,  C07D491/107 ,  C07D403/12 ,  C07D239/48 ,  C07D409/14 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D401/12

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20180085368A1

公开(公告)日：2018-03-29

申请号：US15809011

申请日：2017-11-10

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: A61K31/506 ,  A61K31/551 ,  C07D473/34 ,  C07D487/04 ,  C07D471/10 ,  C07D471/20 ,  C07D471/04 ,  C07D495/20 ,  C07D519/00 ,  A61K31/519 ,  A61K31/52 ,  C07D491/20

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

公开(公告)号：US20170121339A1

公开(公告)日：2017-05-04

申请号：US15337237

申请日：2016-10-28

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20230071483A1

公开(公告)日：2023-03-09

申请号：US17720529

申请日：2022-04-14

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Justin T. ERNST ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Chinh Viet TRAN ,  Garrick Kenneth PACKARD ,  Alan X. XIANG ,  Christian NILEWSKI ,  Theo MICHELS

IPC: C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D491/153 ,  C07D491/16 ,  C07D491/20 ,  C07D498/14 ,  C07D519/00

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20220119387A1

公开(公告)日：2022-04-21

申请号：US17484564

申请日：2021-09-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. REICH ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11286268B1

公开(公告)日：2022-03-29

申请号：US16916820

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Samuel Sperry ,  Alan X. Xiang ,  Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Mike Shaghafi ,  Theo Michels ,  Christian Nilewski ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan Grubbs ,  Kaveri Urkalan ,  Takasuke Mukaiyama

IPC: C07D519/00 ,  C07D495/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11130757B2

公开(公告)日：2021-09-28

申请号：US16661507

申请日：2019-10-23

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst ,  Bennett C. Borer ,  Samuel Sperry ,  Jo Ann Z. Wilson

IPC: A61K31/506 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US10112955B2

公开(公告)日：2018-10-30

申请号：US15337184

申请日：2016-10-28

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D239/42 ,  C07D239/49 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04 ,  C07D239/48 ,  C07D409/14 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D491/107

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US10000487B2

公开(公告)日：2018-06-19

申请号：US15355271

申请日：2016-11-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Paul A. Sprengeler ,  Seigfried H. Reich ,  Stephen E. Webber ,  Justin T. Ernst

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D471/10

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US09814718B2

公开(公告)日：2017-11-14

申请号：US15611966

申请日：2017-06-02

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Siegfried H. Reich ,  Paul A. Sprengeler ,  Stephen E. Webber ,  Alan X. Xiang ,  Justin T. Ernst

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/52 ,  A61K31/519 ,  C07D487/04 ,  A61K31/551 ,  C07D519/00 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  C07D471/10 ,  C07D473/34

CPC classification number: A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/551 ,  C07D471/04 ,  C07D471/10 ,  C07D471/20 ,  C07D473/34 ,  C07D487/04 ,  C07D491/20 ,  C07D495/20 ,  C07D519/00

Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.